Loading patent…
AssigneeBioArctic Neuroscience AB
InventorsLars Lannfelt, Joakim Bergström, Martin Ingelsson, Pär Gellerfors
Estimating the term…
A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody.
An antibody, produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein, wherein the antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered.
An antibody, produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein, wherein the antibody has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display.
Dependencies are inferred from the claim text.